• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    T

    The Prince Charles Hospital

    3,852论文总数
    6.5万引用总数

    The Prince Charles Hospital (TPCH) is a major teaching and tertiary referral hospital in the northern suburb of Chermside in Brisbane, Australia. TPCH is a public hospital operated by Metro North Health, the largest health service in Queensland Health. The hospital is described to be the "leading cardiothoracic hospital in Australia", and provides services to patients in Queensland and northern New South Wales. The Prince Charles Hospital employs 3,390 staff, including 635 doctors and 2,150 nursing staff, and provides around 340,000 episodes of care each year. Beyond cardiothoracic care, The Prince Charles Hospital also provides general surgical and medical services, including both a paediatric and adult emergency medicine department, and specialist outpatient, rehabilitation, and palliative care services. The hospital is actively involved in medical research, and has research partnerships with the University of Queensland, the Queensland University of Technology, and the Australian Catholic University.

    论文量&引用量时间轴

    机构学者

    论文(3859)

    年份
    起
    –
    止
    排序
    1Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
    Steven D Nathan,Peter Smith,Chunqin Deng, Maria De Salvo,Wim Wuyts, Juana Pavie-Gallegos,Jin Woo Song,Mordechai R Kramer,Christopher S King,John A Mackintosh,Daniel Chambers, Georgina Viviana Miranda,

    BACKGROUND:Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical observation. METHODS:In this phase 3, double-blind trial, we randomly assigned patients with IPF to receive inhaled treprostinil or placebo (12 breaths four times daily) over a period of 52 weeks. The primary end point was the change from baseline in the absolute forced vital capacity (FVC) at week 52. Secondary end points, which were analyzed in a prespecified order to control for multiplicity, were clinical worsening and acute exacerbation of IPF (each assessed in a time-to-event analysis), death by week 52, and the change from baseline in the percentage of predicted FVC, quality of life, and the diffusing capacity of the lungs for carbon monoxide by week 52. Safety was also assessed. RESULTS:A total of 593 patients underwent randomization and received at least one dose of treprostinil (298 patients) or placebo (295 patients). Of these, 463 patients (224 in the treprostinil group and 239 in the placebo group) completed the trial assessments through week 52. The mean age of the patients was 71.7 years, 80.1% were men, the mean FVC at baseline was 76.8%, and 75.4% of the patients were receiving background antifibrotic therapy. The median change in FVC at week 52 was -49.9 ml (95% confidence interval [CI], -79.2 to -19.5) in the treprostinil group and -136.4 ml (95% CI, -172.5 to -104.0) in the placebo group; the between-group difference in the change in FVC was 95.6 ml (95% CI, 52.2 to 139.0; P<0.001). Clinical worsening occurred in 81 patients (27.2%) in the treprostinil group and 115 patients (39.0%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.53 to 0.95; P = 0.02). No substantial between-group difference in the time to IPF exacerbation was observed, and so no further inferences with regard to subsequent secondary end points were made. The most common adverse event was cough, reported in 48.3% of the patients in the treprostinil group and 24.1% of those in the placebo group. Discontinuation of treprostinil or placebo occurred in 33.6% and 24.7%, respectively, with approximately half these patients citing adverse events as the primary reason for discontinuation. CONCLUSIONS:In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).

    2026The New England journal of medicine(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2A Consensus of International Experts on Definition, Sampling, Treatment, and Prevention of Peripheral Extracorporeal Membrane Oxygenation Cannula-Site Infection Obtained by the Delphi Method: the SAVECMO Study
    Paul Masi,Darryl Abrams,Ali Ait Hssain,Martin Balik,Nicholas A. Barrett,Lars Mikael Broman,Luigi Camporota, Yih-Sharng Chen,Alain Combes,Daniel De Backer,Lorenzo Del Sorbo,Rodrigo Diaz,

    Nosocomial infections are common in patients receiving extracorporeal membrane oxygenation (ECMO), with ECMO cannula-site infections (ECMO-CSI) being the most frequent infections directly related to the ECMO run. These infections can significantly impact patient outcomes. Currently, no adult guidelines exist for the prevention, diagnosis, and/or treatment of peripheral ECMO-CSI, resulting in heterogeneity in both clinical practice and research findings. We conducted a Delphi study involving 39 international experts in ECMO management. The experts participated in four Delphi rounds to reach consensus on various aspects of ECMO-CSI complicating peripheral ECMO (central ECMO excluded), including definition, clinical suspicion, diagnostic methods, preventive measures, and treatment. Consensus was defined as ≥ 70

    2026Intensive Care Medicine(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Major Haemorrhage and Blood Product Utilisation in Patients Receiving VA ECMO for Cardiogenic Shock: a Multicentre Observational Study (OBLEX).
    Hergen Buscher,Le Thi Phuong Thao,Gennaro Martucci,Johannes Gratz,Georg Trummer,Matthieu Schmidt, Melchior Gautier, Alexis Serra,Koji Takeda, Jan-Steffen Pooth, Kevin Rahn,Florian Geismann,

    Haemorrhage and blood product usage are common in venoarterial extracorporeal membrane oxygenation (VA ECMO) and associated with increased mortality. A prospective, investigator-initiated, longitudinal observational cohort study on major haemorrhagic events in 12 ECMO centres from 3 continents for three predefined subgroups (VA ECMO initiated during cardio-pulmonary resuscitation (ECPR), after cardiothoracic surgery (CTS), for cardiogenic shock (CS)). The aim was to describe haemorrhagic complications as well as transfusion practice and anticoagulation for the whole population as well as the subgroups. In addition, independent baseline predictors for red blood cell (RBC) transfusions were evaluated. 545 prospective patients were included between 2019 and 2022 (ECPR 149, CTS 169, CS 227). Hospital mortality was 46

    2026Critical Care(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Mobile Health Pulmonary Rehabilitation (M-Pr): a Randomised Controlled Equivalence Trial.
    Sarah E Brown, Sally Wootton, Marita T Dale,Jennifer A Alison,Andrew S L Chan,Marlien Varnfield,Ian Yang,Michelle Cunich,Zoe J McKeough

    BACKGROUND:Mobile health (mHealth) is a novel model of care that may overcome barriers to pulmonary rehabilitation (PR) access. This study determined if mHealth PR was equivalent to centre-based PR (CB-PR) in improving exercise capacity and health status in people with chronic obstructive pulmonary disease (COPD). METHOD:Single-blinded, multicentre, randomised controlled equivalence trial using an intention-to-treat analysis. Participants completed 8 weeks of either mHealth PR, using the mobile PR (m-PR) application and supported by telephone calls, or CB-PR. Co-primary outcomes, measured at baseline and end-intervention, were change in 6 minute walk distance (6MWD) and COPD assessment test (CAT) score, with an equivalence margin of 30 m and 2 points, respectively. RESULTS:90 participants were randomised (mean (SD), m-PR n = 44: age 75 (7) years; forced expiratory volume in one second (FEV1) 58 (15) % predicted; CB-PR n = 46: age 75 (6) years; FEV1 55 (14) % predicted) with 38 m-PR participants and 42 CB-PR participants completing at least one primary outcome. At end-intervention, there was no between-group difference in 6MWD (mean difference (MD) 13 m, 95% CI -6 to 31), indicating equivalence of m-PR to CB-PR. There was a significant between-group difference in CAT score (MD -4.9 points, 95% CI -7.2 to -2.6), with both limits of the CI exceeding the equivalence margin, indicating superiority of m-PR. CONCLUSION:An mHealth PR programme resulted in equivalent improvements in exercise capacity and superior improvements in health status when compared with CB-PR in people with COPD. mHealth PR could be effective as a management option for people with COPD with adequate digital literacy. TRIAL REGISTRATION NUMBER:ACTRN12619001253190.

    2026Thorax(2026)引用:2
    引用
    AI阅读
    加入学术空间
    5Co-design, Implementation, and Evaluation of a Nested Diabetes Model of Care for Adults with Cystic Fibrosis: a Mixed Methods Pre-Post Implementation Study.
    Shanal Kumar,Daniel Smith,Vanessa Moore,Angela Matson

    BACKGROUND:Cystic fibrosis (CF) is a genetic disease with increasing life expectancy due to advances in treatment. However, this increased life expectancy has led to new health challenges, especially diabetes. Nearly 25% of adults with CF develop diabetes, but only a minority receive endocrinology care. OBJECTIVE:This study aimed to co-design, implement, and evaluate a nested diabetes model of care (MOC) for adults with CF and diabetes in a single tertiary adult CF center in Australia. METHODS:We used several implementation frameworks to co-design the MOC with consumer and provider end-users. Following MOC implementation, we used database-driven analytics to evaluate changes in the primary clinical outcome (HbA1c) pre and post study at 1 year. A mixed methods approach was used to evaluate secondary clinical and non-clinical outcomes. RESULTS:The MOC promoted multidisciplinary collaboration and streamlined patient journeys, leading to high engagement. Thus, 76.7% of the entire CF cohort with confirmed diabetes was reviewed within the first year of operationalization. Engagement with the MOC was associated with a statistically significant decline in HbA1c (-0.54% vs +0.33%, p- value 0.004) and a 0.22% [95% CI 0.19 -0.32] per month increment in percent predicted forced expiratory volume (ppFEV1). CONCLUSION:Our co-designed MOC demonstrated high engagement as well as improving glycemic management and lung function in adults with CF and diabetes. Our approach to CF diabetes care may reduce the treatment burden in the order of initiating a new diabetes medication while concurrently enhancing end-user experiences of health care. SPANISH ABSTRACT:http://links.lww.com/IJEBH/A473.

    2026JBI evidence implementation(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3859 篇论文

    合作机构(100)

    昆士兰大学合作论文 538
    Royal Brisbane and Women''s Hospital,Queensland Health,Queensland Government合作论文 178
    昆士兰科技大学合作论文 178
    亚历山大公主医院合作论文 173
    皇家阿尔弗雷德王子医院合作论文 132
    格里菲斯大学合作论文 124
    St Vincent''s Hospital,St Vincent''s Health合作论文 118
    莫纳什大学合作论文 113
    悉尼大学合作论文 111
    皇家阿德莱德医院合作论文 105

    机构统计